Clinical utility of the UCSD Performance-Based Skills Assessment—Brief (UPSA-B) in adults living with HIV: Associations with neuropsychological impairment and patient-reported everyday functioning difficulties

Raeanne C. Moore1,2*, Emily W. Paolillo3, Anne Heaton1, Pariya L. Fazeli4, Dilip V. Jeste1,5, David J. Moore1

1 Department of Psychiatry, University of California San Diego, San Diego, California, United States of America, 2 VA San Diego Healthcare System, San Diego, California, United States of America, 3 San Diego State University/University of California San Diego, San Diego Joint Doctoral Program in Clinical Psychology, San Diego, California, United States of America, 4 UAB School of Nursing, The University of Alabama at Birmingham, Birmingham, Alabama, United States of America, 5 Stein Institute for Research on Aging, University of California San Diego, San Diego, California, United States of America

* r6moore@ucsd.edu

Abstract

Objective

Requiring only 10–15 minutes to complete, the UCSD Performance-Based Skills Assessment (UPSA-B) has high clinical utility as a brief measure of functional capacity. This study aimed to validate the UPSA-B in adults living with HIV/AIDS (HIV+), and identify whether the UPSA-B can be used as an indicator of functional dependence in this population.

Method

One hundred and three HIV+ adults and 91 HIV- adults completed a comprehensive neuropsychological and neuromedical battery, including a self-report measure of functional status (IADL Dependence vs. IADL Independence), an objective measure of functional capacity (UPSA-B), and a self-report measure of mood states including a subscale related to cognitive difficulties (Profile of Mood States [POMS]-Confusion/Bewilderment subscale).

Results

HIV+ participants had significantly lower UPSA-B scores than their HIV- counterparts \( p = 0.02 \), although this fell to a trend \( p = 0.08 \) when including covariates. Among the HIV+ group, higher UPSA-B scores were related to better neuropsychological ability, but unrelated to self-reported functional independence. Conversely, UPSA-B scores were unrelated to participant-reported cognitive difficulties on the POMS Confusion/Bewilderment subscale. An ROC curve was generated to determine the optimal UPSA-B value for discriminating between normal neuropsychological functioning versus neuropsychological impairment,
with results indicating an optimal cutoff of 79. The UPSA-B identified HIV+ persons with cognitive impairment with 70.9% accuracy.

**Conclusions**

The UPSA-B was able to differentiate neuropsychological impairment from no impairment among HIV+ participants and holds promise as a clinical screening tool in this population. However, indicators of functional disability among adults living with HIV is still not well understood and is likely multifactorial in nature. These data highlight the complex interplay between objective functional capacity, neurocognitive ability, subjective cognitive symptoms, and functional dependence.

**Introduction**

HIV is a chronic illness frequently resulting in diminished capacity to function independently [1–3]. Such impairments in everyday (“real-world”) functioning are often characterized by declines in basic and instrumental activities of daily living (e.g., housekeeping, cooking) [1], impaired driving ability [4], poor HIV disease management [2,5], increased difficulties in vocational functioning [1,6], and increased rates of unemployment [1,2,7,8]. In some regions, including the United States and South Africa, these HIV-related functional impairments contribute to severe economic burden, as decreases in productivity and labor supply may significantly decrease gross domestic product growth rate [9,10]. Additionally, the reduced ability to care for oneself and properly manage HIV disease (e.g., medication management/adherence) not only poses an individual risk for accelerated disease progression and mortality [11], but also poses a notable public health concern (e.g., the possibility of higher HIV transmission).

Everyday functioning impairments among people living with HIV/AIDS may be due to one or a combination of several factors. Presence of HIV-associated neurocognitive disorders (HAND) are one of the strongest and most consistent correlates of everyday functioning difficulties in the context of HIV/AIDS, with neuropsychologically impaired individuals often performing worse on domains of functional ability compared to neuropsychologically intact individuals [1,3,6,12,13]. Specifically, impairment on neuropsychological (NP) ability domains of executive function, learning, attention/working memory, and verbal abilities are most strongly associated with functional impairment [1]. Functional ability among individuals living with HIV/AIDS is also related to other factors such as mood (e.g., depression) [1,14], substance use [7], and inadequate motivation (e.g., apathy) [15]. This differs from other clinical populations in which functional impairments are more strongly and directly tied to cognitive deficits (e.g., Alzheimer’s disease) [16]. As such, there may be several types of assessments by which we can identify those at risk for functional impairments in the HIV/AIDS clinical population.

Healthcare providers are in need of accurate methods to determine whether someone has basic skills needed to live independently or participate in vocational activities. Currently, researchers and clinicians use several different methods for measuring everyday functioning in people living with HIV/AIDS. One widely accepted and used measure for determining if an individual has the abilities necessary for independent living (i.e., functional independence) is the self-reported Lawton and Brody instrumental activities of daily living (IADL) questionnaire [1,17]. This measure assesses the level of competency with which individuals are able to perform everyday tasks (e.g., housekeeping, managing finances, buying groceries), if they have
difficulty, or need assistance to do these tasks. When using the IADL questionnaire, functional
dependence is determined when individuals report substantial difficulties or needing substan-
tial assistance to successfully perform these critical everyday activities. Additionally, self-
reported recent feelings of difficulties with cognition (e.g., Profile of Mood States [POMS]
Confusion/Bewilderment subscale) [18] are commonly used to determine perceived cognitive
difficulties, and have shown to be associated with functional abilities [14]. While these self-
report measures are prone to retrospective recall and other errors due to cognitive deficits,
state-dependent bias (e.g., depressed mood), or level of insight, they are easy to administer and
brief, making them commonly used and appropriate for clinical settings. Objective NP func-
tioning may also be used to predict functional impairment [1]; however, a comprehensive NP
assessment is time consuming and may not always be feasible as a measure of functional abil-
ity. Moreover, cognitive impairment is not always indicative of functional impairment among
persons living with HIV [19]. On the other hand, objective performance-based measures of
functional capacity that are brief and easy to administer may hold the most promise as rela-
tively quick, ecologically valid, and accurate direct measures of functional impairment.

One such objective measure of functional capacity is the Brief UCSD Performance-Based
Skills Assessment (UPSA-B). This measure was originally developed for assessment of every-
day functioning in adults with severe mental illness [20,21], and has been validated as an ade-
quate screener and predictor of functional independence and employment in schizophrenia
and bipolar disorder [22–25]. Since its development, the UPSA-B has become a widely used
measure in populations of patients with severe mental illness, with several versions that have
been regionally/culturally adapted and validated, such as the European Spanish version [26],
Swedish version [27], and Japanese version [28]. Computerized and mobile versions of the
UPSA-B (i.e., the C-UPSA and UPSA-M, respectively) have also been developed and validated
for use in schizophrenia [29,30]. Beyond the severely mentally ill population, however,
research on the UPSA in other patient populations is scant [31,32]. Furthermore, the UPSA-B
has yet to be examined as a valid measure of functional impairment in people living with
HIV/AIDS, although subcomponents of the UPSA have been incorporated into the Multitask-
ing Test, a test which has been shown to be predictive of IADL dependence among HIV+ adults
[2].

The current study aims to examine the associations between UPSA-B performance, objec-
tive NP functioning, IADL dependence, and self-reported cognitive difficulties among persons
living with HIV in order to determine whether the UPSA-B can be used as a measure of every-
day functioning outcomes among persons living with HIV, which has not previously been
examined in the literature. We hypothesized that HIV+ adults would perform significantly
worse on the UPSA-B compared to HIV- adults. To test the convergent and discriminant
validity of the UPSA-B among people living with HIV/AIDS, we examined the relationships
between UPSA-B performance with global NP ability, IADL dependence, and self-reported
cognitive difficulties, with the hypothesis that UPSA-B performance would be an adequate
indicator of NP impairment and IADL dependence. Lastly, based on literature indicating that
self-reported cognitive difficulties are generally unrelated to objective cognitive impairment
[14,19,33] and UPSA-B performance is related to objective cognitive impairment, we hypothe-
sized cognitive difficulties would be unrelated to UPSA-B scores. If UPSA-B performance is a
stronger indicator of IADL dependence than lengthy comprehensive NP testing or self-
reported cognitive difficulties, the results of the current study may provide support for imple-
mentation of brief measure(s) to better characterize and assess for HIV-associated functional
impairments in both research and clinical settings where such functional determinations are
critical for identification of individuals in need of further treatment, care, and clinical/func-
tional support.
Methods

Participants and design

Participants included 103 HIV+ and 91 HIV- adults from the Multi-Dimensional Successful Aging among HIV-Infected Adults study conducted at the University of California, San Diego (UCSD). Baseline data were examined in this study. Participants were matched for age and race/ethnicity, but not sex or education. The UCSD Institutional Review Board approved this study, and all participants provided written, informed consent. Exclusion criteria for HIV+ and HIV- individuals were minimal: 1) diagnosis of a psychotic disorder or mood disorder with psychotic features; 2) presence of a neurological condition (other than HIV infection) that could negatively impact cognitive functioning (e.g., Alzheimer’s disease, stroke, traumatic brain injury); and 3) positive urine toxicology for alcohol or drugs (excluding marijuana) on the day of testing. All participants were tested for HIV infection using an HIV/HCV finger stick point of care test (Abbott RealTime HIV-1 test, Abbott Laboratories, Illinois, USA). No participants who reported being HIV- at screening tested positive for HIV or Hepatitis C (HCV).

Participants were reviewed for severe confounding neuromedical conditions, not captured by the exclusion criteria or screening, that might negatively affect neurocognitive and everyday functioning and hinder our ability to attribute impairment to direct effects of HIV. We started with 116 HIV+ participants, but 13 participants were classified as severely confounded (e.g., cerebrovascular accident, myocardial infarction, congestive heart failure, and/or moderate-to-severe liver disease) and excluded from analyses, which gave us the final HIV+ sample size of 101 (Mean age = 50.3 years; SD = 8.5; range: 35–65 years) used in the present study. One of the HIV- participants had a severe confound yielding a sample size of 91 HIV- for the present study.

Measures

Neuropsychological battery. A standard HIV Neurobehavioral Research Program (HNRP) neuropsychological battery covering seven neurocognitive domains was used in the present study [1]. This battery was designed in accordance with international consensus conference recommendations and has published norms that correct for demographic effects [age, education, sex, and (when appropriate) race/ethnicity] [34,35]. Cognitive domains assessed include: verbal fluency, attention/working memory, abstraction/executive functioning, learning, memory (delayed recall), speed of information processing, and complex motor skills [35]. Table 1 contains the individual neuropsychological tests that comprise this battery. Raw scores from the neuropsychological tests were converted to demographically-adjusted T-scores (M = 50, SD = 10 in healthy subjects). Global and domain-specific continuous T-scores were used in our comparisons of cognition with other study variables.

To derive domain-based and global deficit scores (GDS), T-scores were subsequently converted into averaged deficit scores, ranging from 0 (no impairment) to 5 (severe impairment) [36]. A GDS Impairment variable is created such that participants with GDS scores greater than 0.5 are deemed neurocognitively impaired, whereas GDS scores less than or equal to 0.5 are deemed to have cognition within normal limits. The GDS Impairment variable was used in the ROC analysis. Lastly, premorbid intellectual functioning was assessed via the Wide Range Achievement Test 4th Edition (WRAT-4) Word Reading subtest.

Everyday functioning measures. Functional Dependence: Functional dependence vs. independence in instrumental activities of daily living (IADLs) was determined using a modified version of the Lawton and Brody scale (Heaton et al., 2004). The IADL questionnaire...
includes questions of managing finances, using the telephone, cooking, buying groceries, working, transportation, understanding of written and viewed material, social activities, and childcare. The IADL is a self-report measure that asks participants to answer questions relating to the level of assistance needed currently compared to when they were at their highest level of functioning. If a decline in functioning in at least two domains was reported, participants were classified as IADL Dependent. This IADL classification approach has been validated in a normative sample compared to one with cognitive impairment [1]. Individuals classified as both NP impaired and IADL Dependent would be diagnosed as having Mild Neurocognitive disorder (MND) or HIV-associated Dementia (HAD) depending on severity of neuropsychological impairments, whereas NP impaired participants without IADL dependence would be diagnosed as having Asymptomatic Neurocognitive Impairment (ANI; i.e. Frascati criteria)[34].

Performance-Based Measure of Functional Capacity: The UCSD Performance-Based Skills Assessment-Brief (UPSA-B) [21,24] was used to assess participants’ capacity to perform tasks similar to those encountered in daily life. The UPSA-B was developed through the use of factor analysis (20) and consists of two of the five subscales from the full UPSA: 1) Financial skills and 2) Communication skills. As opposed to the Computerized UPSA (C-UPSA; 29) and UPSA Mobile App (UPSA-M; 30), the UPSA-B uses tangible props to simulate real-world tasks. This task requires approximately 10–15 minutes to complete. Assessment of financial skills involves tasks in which participants handle fake money (i.e., dollar bills, coins, and checks) to count, make change, and pay bills. Assessment of communication skills involves tasks in which participants use a disconnected landline telephone to simulate making calls (e.g., directory assistance, doctor’s office) to communicate requested or necessary information. In a review of instruments for measuring functional recovery in those diagnosed with serious mental illness, the UPSA-B received the highest overall rating (25). Total percent correct is calculated for each subscale and converted to a standardized score ranging from 0–50. A summary score is then calculated by summing the two domain scores for a total score ranging from 0–100, with higher scores indicating better functional capacity.

**Participant-reported cognitive difficulties.** The Profile of Mood States (POMS) questionnaire assesses psychological distress. This measure consists of six subscales: Tension-Anxiety, Depression-Dejection, Anger-Hostility, Vigor-Activation, Fatigue-Inertia, and

| Cognitive Domain | Tests |
|------------------|-------|
| Speed of Information Processing | WAIS-III Digit Symbol Search, Trail Making Test, Part A, Stroop Color Trial |
| Learning and Memory (2 domains) | Hopkins Verbal Learning Test-Revised, Brief Visuospatial Memory Test-Revised |
| Abstraction/Executive Functioning | Wisconsin Card Sorting Test (64-item), Trail Making Test, Part B, Stroop Color Word Trial |
| Verbal Fluency | Controlled Oral Word Association Test, Category Fluency (Animals), Category Fluency (Actions) |
| Attention/Working Memory | WAIS-III Letter-Number Sequencing, PASAT (1st channel only) |
| Motor | Grooved Pegboard Test (Dominant & Non-dominant Hands) |

*Note. WAIS-III: Wechsler Adult Intelligence Scale 3rd Edition; PASAT: Paced Auditory Serial Addition Task.*

https://doi.org/10.1371/journal.pone.0183614.t001
Confusion-Bewilderment [18]. The 7-item Confusion-Bewilderment subscale, which includes items on forgetfulness, problems concentrating, and muddled or uncertain thoughts, was used in this study to assess subjective cognitive functioning (i.e., cognitive difficulties). Participants rate their experience of cognitive difficulties during the past week on a scale from 0 = not at all to 4 = extremely, for a total subscale score ranging from 0–28. Higher scores indicate more symptoms.

**HIV disease characteristics.** All participants completed a standardized research neuromedical evaluation, including a thorough medical history, assessment of current HIV symptoms and antiviral medications, a physical and neurological evaluation, CDC staging, and a blood draw. For individuals with HIV-infection, HIV RNA viral load (VL) was measured by reverse transcriptase-polymerase chair reaction (Abbott m2000 HIV 1,2; lower limit of quantitation 40 copies per milliliter).

**Statistical Analyses.** Data were examined for normality and three sets of analyses were conducted. First, t-tests were performed to determine group differences on the UPSA-B total scores and each of the two domains of functioning measured on the UPSA-B (finances; communication). Next, among the HIV+ group, the following analyses were performed (1): Pearson correlations were performed to determine the relationships between global neuropsychological ability (i.e., global T-scores), UPSA-B scores, and POMS Confusion/Bewilderment scores, and 2) Additional t-tests were performed to determine if UPSA-B and POMS scores differed based on the presence or absence of functional dependence.

Based on results of the first analyses, we plotted a receiver operating characteristic (ROC) curve for the UPSA-B to determine the optimal cutoff in discriminating between cognitive impairment vs. no cognitive impairment (using the GDS Impairment variable). The optimal cutoff score was determined by producing a Youden’s index value, which is one minus specificity subtracted from sensitivity [37,38]. The area under the curve (AUC) with 95% confidence intervals (CI) was used as an indicator of the ability of the UPSA-B to differentiate between neurocognitive status.

**Results**

**Comparison of HIV+ and HIV- performance on the UPSA-B**

See Table 2 for full descriptive statistics of our sample. HIV+ participants’ total score on the UPSA-B was significantly lower than the HIV- participants (p = 0.02). The HIV+ participants performed significantly worse in the Financial Skills subtest compared to the HIV- participants, and their performance was lower than the HIV- participants in Communication Skills subtest at a trend-level (see Table 3). The groups did not differ on age or race/ethnicity. Given that the HIV- group was significantly more educated and had more females than the HIV+ group, we repeated these analyses covarying for sex and education. When these demographic variables were controlled for, UPSA-B total scores did not significantly differ between the groups (F = 3.19, p = 0.08), although a trend-level finding was still observed. The HIV+ group had significantly lower global neuropsychological scores, had a greater rate of IADL dependence, and had more cognitive difficulties than the HIV- group (see Table 2).

**Associations between performance on the UPSA-B, neuropsychological performance, and self-reported IADL independence in HIV+ adults**

Among the HIV+ participants, 40 (39%) met criteria for neuropsychological impairment (via GDS Impairment), and 27 participants (27%) met criteria for self-reported IADL dependence; 11 participants (28%) had both GDS impairment and IADL dependence. Among HIV
### Table 2. Demographic and clinical characteristics of the participants.

| Demographic Characteristics | HIV+ participants (n = 103) | HIV- participants (n = 91) | t or Ch² | df | p  |
|-----------------------------|-----------------------------|---------------------------|--------|---|---|
| **Age (yrs), M(SD)**        | 50.3(8.5)                   | 51.4(7.6)                 | 0.95   | 192 | 0.35 |
| **Education (yrs), M(SD)**  | 14.0(2.2)                   | 15.0(2.3)                 | 2.82   | 192 | <0.01 |
| **Gender**                  |                             |                           |        |    |    |
| Male, n(%)                  | 87(84.5)                    | 65(71.4)                  | 4.84   | 1  | 0.03 |
| Female, n(%)                | 16(15.5)                    | 26(28.6)                  |        |    |    |
| **Race/Ethnicity**          |                             |                           | 1.70   | 1  | 0.19 |
| White, n(%)                 | 62(61.4)                    | 64(70.3)                  |        |    |    |
| Other, n(%)                 | 39(38.6)                    | 27(29.7)                  |        |    |    |
| **HIV Disease Characteristics** |                             |                           |        |    |    |
| Est. duration of HIV (yrs), M(SD) | 17.0(8.8)    | —                        |        |    |    |
| AIDS, n(%)                  | 61(59.2)                    | —                        |        |    |    |
| cART©, n(%)                 | 92(89.3)                    | —                        |        |    |    |
| Nadir CD4 (cells/μl)        | 181.5(58.0,353.0)           | —                        |        |    |    |
| Current CD4 (cells/μl)      | 628.5(432.0,846.3)          | —                        |        |    |    |
| Plasma detectable, n(%)     | 5(6.1)                      | —                        |        |    |    |
| **Medical Characteristics** |                             |                           |        |    |    |
| Hepatitis C, n(%)           | 21(20.4)                    | 0(0)                     | 20.81  | 1  | <0.01 |
| Body Mass Index, M(SD)      | 27.5(6.0)                   | 27.4(6.6)                 | 0.10   | 188 | 0.92 |
| SF-36 Physical Health Composite Score, M(SD) | 70.1(24.1)  | 84.2(18.9)               | 4.46   | 188 | <0.01 |
| **Psychiatric Characteristics** |                             |                           |        |    |    |
| Current Major Depressive Disorder, n(%) | 12(11.7)         | 0(0)                     | 12.00  | 1  | <0.01 |
| Alcohol dependence©, n(%)   | 32(31.1)                    | 9(10.1)                   | 13.02  | 1  | 0.001 |
| Non-alcohol dependence©, n(%) | 47(46.5)                | 8(9.0)                    | 32.44  | 176 | <0.001 |
| **Cognition and Daily Functioning** |                             |                           |        |    |    |
| Premorbid IQ, M(SD)         | 103.8(13.8)                 | 106.9(13.6)               | 1.58   | 190 | 0.12 |
| GDS impairment, n(%)        | 40(38.8)                    | 23(25.3)                  | 4.05   | 1  | 0.04 |
| IADL dependence, n(%)       | 27(26.2)                    | 5(5.5)                    | 15.06  | 1  | <0.001 |
| POMS, M(SD)                 | 7.0(5.7)                    | 3.4(3.4)                  | 5.24   | 190 | <0.001 |

Note.

©Data represent medians with interquartile ranges in parentheses;
©n = 82;
©5 additional participants are a non-cART regimen;
©Denotes a lifetime diagnosis;
©includes cannabis, cocaine, hallucinogens, inhalants, methamphetamine, opioids, PCP, or other substances;
©measured with the Wide Range Achievement Test (WRAT); IADL = Instrumental Activities of Daily Living; POMS = Profile of Mood State

https://doi.org/10.1371/journal.pone.0183614.t002

### Table 3. Comparison of HIV+ and HIV- participants' performance on the UPSA-B.

| UPSA-B                          | HIV+ participants (n = 103), mean(SD); range | HIV- participants (n = 91), mean(SD) | t       | df  | p     |
|---------------------------------|---------------------------------------------|--------------------------------------|---------|-----|-------|
| Finance Subscale Score©         | 42.6(6.5); 23–50                            | 44.3(5.0); 23–50                     | 2.00    | 192 | 0.05  |
| Communication Subscale Score©   | 37.0(8.5); 11–50                            | 39.0(7.5); 22–50                     | 1.80    | 192 | 0.07  |
| UPSA-B Total Score©             | 79.6(11.4); 49–100                          | 83.3(10.1); 51–100                   | 2.40    | 192 | 0.02  |

Note. UPSA-B = UCSD Performance-Based Skills Assessment-Brief;
©Possible range of scores for each subscale: 0–50;
©Possible range for total score: 0–100.

https://doi.org/10.1371/journal.pone.0183614.t003
Participants, higher UPSA-B scores were related to higher education levels ($r = 0.26$, $p = 0.01$) and White race ($r = 0.31$, $p < 0.01$), but were unrelated to age ($r = 0.01$, $p = 0.96$), gender ($r = 0.03$, $p = 0.78$), duration of HIV ($r = 0.04$, $p = 0.66$), CD4 counts (nadir CD4: $r = 0.06$, $p = 0.54$; current CD4: $r = 0.09$, $p = 0.39$), detectable viral loads ($r = 0.06$, $p = 0.58$), AIDS status ($r = 0.07$, $p = 0.50$), ARV status ($r = 0.09$, $p = 0.40$) or HCV serostatus ($r = 0.05$, $p = 0.64$). Lower UPSA-B total scores were related to lower premorbid intellectual functioning (i.e., WRAT Word Reading score; $r = 0.27$, $p < 0.01$) and lower global neuropsychological scores ($r = 0.41$, $p < 0.001$); in addition, lower UPSA-B scores were identified among those with GDS-derived neuropsychological impairment (M UPSA-B = 74.5, SD = 10.9) as compared to those without NP impairment (M UPSA-B = 82.8, SD = 10.6; $t = 3.84$, $p < 0.001$). UPSA-B total scores were unrelated to self-reported IADL independence vs. dependence ($t = 0.93$, $p = 0.35$) or POMS Confusion/Bewilderment scores ($r = 0.17$, $p = 0.09$).

Follow-up analyses examining the specific neurocognitive domains related to UPSA-B scores indicated positive, significant correlations at $p < 0.05$ between performance in all neurocognitive domains (verbal ability: $r = 0.40$, $p < 0.001$; executive functions: $r = 0.34$, $p < 0.001$; speed of information processing: $r = 0.30$, $p < 0.01$; learning: $r = 0.25$, $p = 0.01$; recall: $r = 0.21$, $p = 0.03$; working memory: $r = 0.45$, $p < 0.01$; motor ability: $r = 0.22$, $p = 0.03$).

**Discussion**

Significant differences in UPSA-B performance were found between HIV+ and HIV- participants, although these results became nonsignificant when we controlled for group differences in education and sex. This finding suggests the UPSA-B may be a sensitive assessment of functional capacity among HIV+ adults, but future studies are needed to further evaluate UPSA-B differences among those with and without HIV before more definitive conclusions can be drawn. The UPSA was initially developed to assess functional capacity among individuals with serious mental illness, who generally have more prominent and severe cognitive and functional deficits than persons living with HIV. Future corroboration of our hypothesis with significant results, however, may indicate that the UPSA-B might be sensitive to the milder neurocognitive and functional impairments of people living with HIV/AIDS. Overall, there was a broad range of UPSA-B scores among our HIV+ participants (M = 79.6, SD = 11.4, range = 49–100), and previous work has demonstrated the UPSA-B is not a good indicator of functional capacity among individuals without neuropsychological impairments [39]. More challenging performance-based measures of functional capacity, such as the Advanced Finances Test [1] or the Multitasking Test [2] may be more appropriate if the goal is to either characterize functional capacity among those with intact cognition or differentiate persons living with HIV/AIDS from persons without HIV/AIDS; however, this needs to be explored in future studies.
The UPSA-B appears to have utility in this population as a brief screener for potential neurocognitive impairment. Consistent with studies in other populations [40], and supporting the convergent validity of the UPSA-B with neurocognitive ability, we found global neuropsychological performance was related to functional capacity as measured by the UPSA-B.

![Receiver operating curve for UPSA-B predicting neurocognitive impairment](https://doi.org/10.1371/journal.pone.0183614.g001)

| UPSA-B | <74.5 | <76.5 | <79.0* | <81.0 | <82.5 |
|--------|-------|-------|--------|-------|-------|
| Sensitivity | 81.0 | 76.2 | 69.8 | 58.7 | 57.1 |
| Specificity | 52.5 | 57.5 | 72.5 | 77.5 | 77.5 |
| Yuden’s Index | 33.5 | 33.7 | 42.3 | 36.2 | 34.6 |
| PPV | 72.9 | 73.8 | 80.0 | 80.4 | 80.0 |
| NPV | 63.6 | 60.5 | 72.5 | 54.4 | 53.4 |
| Accuracy | 69.9 | 66.9 | 70.9 | 66.0 | 65.0 |

*Notes. UPSA-B = UCSD Performance Based Skills Assessment-Brief; PPV = positive predictive value (proportion of participants with higher scores who were correctly classified as not impaired); NPV = negative predictive value (proportion of participants with lower scores who were correctly classified as having cognitive impairment). Maximum sensitivity and specificity.

Fig 1. Receiver operating curve for UPSA-B predicting neurocognitive impairment.

https://doi.org/10.1371/journal.pone.0183614.g001
Examination of specific neuropsychological domains showed that the UPSA-B was associated with performance in all domains. Better UPSA-B performance was associated with higher education levels and White race, but was unrelated to age, gender, HIV disease characteristics, or HCV serostatus, suggesting that other instruments may be more appropriate in more diverse and/or lower educated cohorts.

While the UPSA-B has historically been used as an outcome measure for neurocognitive impairment or functional dependence, we chose to examine the use of the UPSA-B as a screening tool for neurocognitive impairment for clinical reasons. Adults living with HIV who are experiencing neurocognitive problems are more likely to seek treatment from their primary care physician or an infectious disease specialist than from a neuropsychologist. By design, the UPSA does not require a higher level degree, such as a Master’s or Doctorate degree, to administer and interpret (as opposed to neuropsychological tests), and could therefore be administered by staff at a primary care, infectious disease, or occupational therapy clinic. We found that the UPSA-B was able to differentiate HIV+ participants with and without neurocognitive impairment 70.9% of the time. The UPSA-B appears to be a sensitive neurocognitive screener, especially among those without cognitive impairment (positive predictive value [PPV] = 80.0%), and it has adequate ability to quickly identify persons living with HIV/AIDS who have possible cognitive impairment (negative predictive value [NPV] of 72.5%). Therefore, we recommend that patients with UPSA-B scores of ≤79 be referred for further neuropsychological evaluation to more accurately assess and determine presence of HAND.

Limitations
Our study has several limitations. First, the data were cross-sectional, which limits our ability to make inferences regarding causality. Future work is needed to determine whether the UPSA-B could predict declines in cognition. Second, one quarter (25%) of the HIV-comparison participants met criteria for cognitive impairment, which is higher than the average population of HIV- adults. The substantial number of HIV- participants with cognitive impairment may have impacted the results, in that these were not a representative sample of comparison participants. In addition, our sample was relatively healthy from an HIV standpoint, with 94% of the HIV+ participants currently virally suppressed, which also limits the generalizability of our findings to less healthy HIV+ samples. The UPSA-B did not perform well for non-white and lower educated individuals, and there is a need for more ubiquitous but sensitive tasks of everyday functioning. Another limitation of our study is our IADL measure is a retrospective, self-report measure and categorizes people into IADL dependent or independent. Daily functioning impairments are often more subtle and can change over time in regard to completing complex daily activities, making these impairments difficult to detect. Additionally, our IADL self-report measure is limited in that the definition of “daily functioning” does not capture important domains of daily functioning beyond ADLs and IADLs, such as engagement in productive or cognitively stimulating activities, physical activities, or social activities. While performance-based tests of daily functioning, such as the UPSA-B, may provide a useful snapshot of functional capacity at one time point, it may not fully capture the intricacies or functioning demands of real-world daily functioning. Ambulatory data collection techniques that rely on repeated intra-day assessments of functional behaviors in real-time and in ecologically valid contexts, such as ecological momentary assessment (EMA), hold promise as a mobile assessment tool to assess daily functioning behaviors in HIV [41], and may be more appropriate than self-report measures or performance-based tests in certain contexts.
Conclusions

Overall, functional disability among HIV+ adults is still not well understood and is likely multifactorial in nature. These data highlight the complex interplay between objective functional capacity, neurocognitive ability, subjective cognitive symptoms, and functional dependence. The UPSA-B statistically distinguished people with HIV/AIDS from comparison participants when education and sex were not taken into account; however, this finding was only at a trend level ($p = 0.08$) when these demographic differences were taken into account. On the other hand, and arguably more importantly, the UPSA-B was able to differentiate neurocognitive impairment from no impairment among the HIV+ participants. Differentially, our measure of self-reported cognitive difficulties was unrelated to UPSA-B performance, although there is a need for more sensitive self-report measures of cognitive difficulties [14,19,42]. These results emphasize the clinical importance of considering both objective and self-report data in the determination of a patient’s cognitive and functional abilities.

Acknowledgments

This research was supported by the National Institute of Mental Health (grant number R01 MH099987, P30MH062512, K23 MH107260 (salary support to RCM), R00 AG048762 (salary support to PLF), T32 AA013525 (stipend support to EWP)). None of the authors have a conflict of interest. The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Navy, Department of Defense, National Institutes of Health, nor the United States Government.

Author Contributions

Conceptualization: Raeanne C. Moore, Dilip V. Jeste, David J. Moore.

Data curation: Anne Heaton, Pariya L. Fazeli.

Formal analysis: Raeanne C. Moore.

Funding acquisition: Dilip V. Jeste, David J. Moore.

Investigation: Anne Heaton, Pariya L. Fazeli.

Methodology: Raeanne C. Moore, Dilip V. Jeste, David J. Moore.

Project administration: Dilip V. Jeste, David J. Moore.

Resources: Dilip V. Jeste, David J. Moore.

Supervision: Raeanne C. Moore, Dilip V. Jeste, David J. Moore.

Validation: Dilip V. Jeste, David J. Moore.

Visualization: Raeanne C. Moore.

Writing – original draft: Raeanne C. Moore, Emily W. Paolillo, Anne Heaton, Pariya L. Fazeli.

Writing – review & editing: Raeanne C. Moore, Emily W. Paolillo, Anne Heaton, Pariya L. Fazeli, Dilip V. Jeste, David J. Moore.

References

1. Heaton RK, Marcotte TD, Mindt MR, Sadek J, Moore DJ, Bentley H, et al. (2004) The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 10: 317–331. https://doi.org/10.1017/S1355617704062130 PMID: 15147590
2. Scott JC, Woods SP, Vigil O, Heaton RK, Schweinsburg BC, Ellis RJ, et al. (2011) A neuropsychological investigation of multitasking in HIV infection: implications for everyday functioning. Neuropsychology 25: 511–519. https://doi.org/10.1037/a0022491 PMID: 21401259

3. Woods SP, Iudicello JE, Moran LM, Carey CL, Dawson MS, Grant I, et al. (2008) HIV-associated prospective memory impairment increases risk of dependence in everyday functioning. Neuropsychology 22: 110–117. https://doi.org/10.1037/0894-4105.22.1.110 PMID: 18211160

4. Marcotte TD, Heaton RK, Wolfson T, Taylor MJ, Alhassoon O, Afraa K, et al. (1999) The impact of HIV-related neuropsychological dysfunction on driving behavior. The HNRC Group. J Int Neuropsychol Soc 5: 579–592. PMID: 10645701

5. Thames AD, Kim MS, Becker BW, Foley JM, Hines LJ, Singer EJ, et al. (2011) Medication and finance management among HIV-infected adults: The impact of age and cognition. J Clin Exp Neuropsychol 33: 200–209. https://doi.org/10.1080/13803395.2010.499357 PMID: 20694873

6. Gorman AA, Foley JM, Ettenhofer ML, Hinkin CH, van Gorp WG (2009) Functional consequences of HIV-associated neuropsychological impairment. Neuropsychol Rev 19: 186–203. https://doi.org/10.1007/s11065-009-9095-0 PMID: 19472057

7. Blackstone K, Iudicello JE, Morgan EE, Weber E, Moore DJ, Franklin DR, et al. (2013) Human immunodeficiency virus infection heightens concurrent risk of functional dependence in persons with long-term methamphetamine use. J Addict Med 7: 255–263. https://doi.org/10.1097/ADM.0b013e318293653d PMID: 23648641

8. Heaton RK, Velin RA, McCutchan JA, Gulevich SJ, Atkinson JH, Wallace MR, et al. (1994) Neuropsychological impairment in human immunodeficiency virus-infection: implications for employment. HNRC Group. HIV Neurobehavioral Research Center. Psychosom Med 56: 8–17. PMID: 8197319

9. Hutchinson AB, Farnham PG, Dean HD, Ekwueme DU, del Rio C, Kamimoto L, et al. (2006) The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences. J Acquir Immune Defic Syndr 43: 451–457. https://doi.org/10.1097/01.qai.0000243090.32866.4e PMID: 16980906

10. Thurlow J, Gow J, George G (2009) HIV/AIDS, growth and poverty in KwaZulu-Natal and South Africa: an integrated survey, demographic and economy-wide analysis. J Int AIDS Soc 12: 18. https://doi.org/10.1186/1758-2652-12-18 PMID: 19758444

11. Bangsberg DR, Kroetz DL, Deeks SG (2007) Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep 4: 65–72. PMID: 17547827

12. Cattie JE, Doyle K, Weber E, Grant I, Woods SP, Group HIVNRP (2012) Planning deficits in HIV-associated neurocognitive disorders: component processes, cognitive correlates, and implications for everyday functioning. J Clin Exp Neuropsychol 34: 906–918. https://doi.org/10.1080/13803395.2012.692772 PMID: 22731608

13. Doyle KL, Morgan EE, Morris S, Smith DM, Little S, Iudicello JE, et al. (2013) Real-world impact of neurocognitive deficits in acute and early HIV infection. J Neurovirol 19: 565–573. https://doi.org/10.1007/s13365-013-0218-2 PMID: 24277439

14. Sadek JR, Vigil O, Grant I, Heaton RK, Group H (2007) The impact of neuropsychological functioning and depressed mood on functional complaints in HIV-1 infection and methamphetamine dependence. J Clin Exp Neuropsychol 29: 266–276. https://doi.org/10.1080/13803390600659584 PMID: 17454347

15. Kamrat R, Woods SP, Marcotte TD, Ellis RJ, Grant I, Group HIVNRP (2012) Implications of apathy for everyday functioning outcomes in persons living with HIV infection. Arch Clin Neuropsychol 27: 520–531. https://doi.org/10.1093/acnbl/acs055 PMID: 22705481

16. Boyle KA, Malloy PF, Salloway S, Cahn-Weiner DA, Cohen R, Cummings JL (2003) Executive dysfunction and apathy predict functional impairment in Alzheimer disease. Am J Geriatr Psychiatry 11: 214–221. PMID: 12611751

17. Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9: 179–186. PMID: 5349366

18. McNair DM, Droppelman LF (1981) Manual for the Profile of Mood States. San Diego, CA: Educational and Industrial Testing Services.

19. Thames AD, Becker BW, Marcotte TD, Hines LJ, Foley JM, Ramezani A, et al. (2011) Depression, cognition, and self-appraisal of functional abilities in HIV: an examination of subjective appraisal versus objective performance. Clin Neuropsychol 25: 224–243. https://doi.org/10.1080/13854046.2010.539577 PMID: 21331979

20. Mausbach BT, Harvey PD, Goldman SR, Jeste DV, Patterson TL (2007) Development of a brief scale of everyday functioning in persons with serious mental illness. Schizophr Bull 33: 1364–1372. https://doi.org/10.1093/schbul/sbm014 PMID: 17341468
21. Patterson TL, Goldman S, McKibbin CL, Hughes T, Jeste DV (2001) UCSD Performance-Based Skills Assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr Bull 27: 235–245. PMID: 11354591

22. Mausbach BT, Bowie CR, Harvey PD, Twamley EW, Goldman SR, Jeste DV, et al. (2008) Usefulness of the UCSD performance-based skills assessment (UPSA) for predicting residential independence in patients with chronic schizophrenia. J Psychiatr Res 42: 320–327. https://doi.org/10.1016/j.jpsychires.2006.12.006 PMID: 17303168

23. Mausbach BT, Depp CA, Bowie CR, Harvey PD, Thomquist MH, et al. (2011) Sensitivity and specificity of the UCSD Performance-based Skills Assessment (UPSA-B) for identifying functional milestones in schizophrenia. Schizophr Res 132: 165–170. https://doi.org/10.1016/j.schres.2011.07.022 PMID: 21843926

24. Mausbach BT, Harvey PD, Pulver AE, Depp CA, Wolyniec PS, Thomquist MH, et al. (2010) Relationship of the Brief UCSD Performance-based Skills Assessment (UPSA-B) to multiple indicators of functioning in people with schizophrenia and bipolar disorder. Bipolar Disord 12: 45–55. https://doi.org/10.1111/j.1399-5618.2009.00787.x PMID: 20148866

25. Mausbach BT, Moore R, Bowie C, Cardenas V, Patterson TL (2009) A review of instruments for measuring functional recovery in those diagnosed with psychosis. Schizophr Bull 35: 307–318. https://doi.org/10.1093/schbul/sbn152 PMID: 19023122

26. Garcia-Portilla MP, Gomar JJ, Bobes-Bascaran MT, Menendez-Miranda I, Saiz PA, Muniz J, et al. (2013) Validation of a European Spanish-version of the University of California performance Skills Assessment (Sp-UPSA) in patients with schizophrenia and bipolar disorder. Schizophr Res 150: 421–426. https://doi.org/10.1016/j.schres.2013.07.049 PMID: 24055246

27. Olsson A, Hjartåg F, Norlander T (2012) Psychometric properties of a performance-based measure of functional capacity, the UCSD Performance-based Skills Assessment—Brief version. Psychiatry Res 197: 290–294. https://doi.org/10.1016/j.psychres.2011.11.002 PMID: 22377575

28. Sumiyoshi C, Takaki M, Okahisa Y, Patterson TL, Harvey PD, Sumiyoshi T (2014) Utility of the UCSD Performance-based Skills Assessment-Brief Japanese version: discriminative ability and relation to neurocognition. Schizophr Res Cognition 1: 137–143.

29. Moore RC, Fazeli PL, Patterson TL, Depp CA, Moore DJ, Granholm E, et al. (2015) UPSA-M: Feasibility and initial validity of a mobile application of the UCSD Performance-Based Skills Assessment. Schizophr Res 164: 187–192. https://doi.org/10.1016/j.schres.2015.02.014 PMID: 25799003

30. Moore RC, Harmell AL, Ho J, Patterson TL, Eyler LT, Jeste DV, et al. (2013) Initial validation of a computerized version of the UCSD Performance-Based Skills Assessment (C-UPSA) for assessing functioning in schizophrenia. Schizophr Res 144: 87–92. https://doi.org/10.1016/j.schres.2012.12.028 PMID: 23375625

31. Morgan EE, Doyle KL, Minassian A, Henry BL, Perry W, Marcotte TD, et al. (2014) Elevated intra-individual variability in methamphetamine dependence is associated with poorer everyday functioning. Psychiatry Res 220: 527–534. https://doi.org/10.1016/j.psychres.2014.07.008 PMID: 25081313

32. Henry BL, Minassian A, Perry W (2010) Effect of methamphetamine dependence on everyday functional ability. Addict Behav 35: 593–598. https://doi.org/10.1016/j.addbeh.2010.01.013 PMID: 20167435

33. Zlatar ZZ, Moore RC, Palmer BW, Thompson WK, Jeste DV (2014) Cognitive complaints correlate with depression rather than concurrent objective cognitive impairment in the Successful Aging Evaluation baseline sample. J Geriatr Psychiatry Neurol 27: 181–187. https://doi.org/10.1177/0891988714524628 PMID: 24614203

34. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Chermer M, et al. (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69: 1789–1799. https://doi.org/10.1212/01.WNL.0000287431.88658.B8 PMID: 17914061

35. Heaton RK, Clifford DB, Franklin DR Jr., Woods SP, Ake C, Vaida F, et al. (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75: 2087–2096. https://doi.org/10.1212/WNL.0b013e318200d727 PMID: 21135382

36. Blackstone K, Moore DJ, Franklin DR, Clifford DB, Collier AC, Marra CM, et al. (2012) Defining neurocognitive impairment in HIV: deficit scores versus clinical ratings. Clin Neuropsychol 26: 894–908. https://doi.org/10.1080/13854046.2012.694479 PMID: 22708483

37. Loong TW (2003) Understanding sensitivity and specificity with the right side of the brain. Bmj 327: 716–719. https://doi.org/10.1136/bmj.327.7417.716 PMID: 14512479

38. Fluss R, Faraggi D, Reiser B (2005) Estimation of the Youden Index and its associated cutoff point. Biom J 47: 458–472. PMID: 16161804
39. Moore RC, Harmell AL, Harvey PD, Bowie CR, Depp CA, Pulver AE, et al. (2015) Improving the understanding of the link between cognition and functional capacity in schizophrenia and bipolar disorder. Schizophr Res 169: 121–127. https://doi.org/10.1016/j.schres.2015.09.017 PMID: 26427917

40. Bowie CR, Reichenberg A, Patterson TL, Heaton RK, Harvey PD (2006) Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am J Psychiatry 163: 418–425. https://doi.org/10.1176/appi.ajp.163.3.418 PMID: 16513862

41. Moore RC, Kaufmann CN, Rooney AS, Moore DJ, Eyler LT, Granholm E, et al. (2016) Feasibility and acceptability of ecological momentary assessment of daily functioning among older adults with HIV. Am J Geriatr Psychiatry 25(8): 829–840. https://doi.org/10.1016/j.jagp.2016.11.019 PMID: 28065496

42. Shiffman S, Stone AA, Hufford MR (2008) Ecological momentary assessment. Annu Rev Clin Psychol 4: 1–32. PMID: 18509902